Reckitt Benckiser has boosted its OTC portfolio in emerging markets with the acquisition of Indian group Paras Pharmaceuticals.

The deal, worth around £460m, hands Reckitt control of brands including flu remedy D'Cold, skin treatment Dermicool and anti-fungal cream Ring Guard.

“The acquisition of Paras is another step forward in RB's growth strategy in consumer healthcare,” said Reckitt chief executive Bart Becht (pictured).

“It creates a material healthcare business in India, one of the most promising healthcare markets in the world, with the addition of a number of leading brands.”

Becht added: “We believe Paras has not only extremely good growth potential, when supported by RB's investment and innovation strength; we also expect to realise material synergies as a result of the integration of Paras into Reckitt.”

Read more
Reckitt installs ex-Unilever exec Doherty as new finance chief (24 November 2010)
Reckitt kicks off cold and flu season with £20m ad campaign (15 November 2010)